UAE says Sinopharm vaccine has 86pc efficacy against Covid-19

Published December 9, 2020
A woman holds vials labelled "Covid-19 Coronavirus Vaccine" over dry ice in this illustration taken on Dec 5. — Reuters/File
A woman holds vials labelled "Covid-19 Coronavirus Vaccine" over dry ice in this illustration taken on Dec 5. — Reuters/File

An experimental coronavirus vaccine developed by China National Pharmaceutical Group (Sinopharm) has 86 per cent efficacy, the health ministry of the United Arab Emirates said on Wednesday, citing an interim analysis of late-stage clinical trials.

While the positive data comes soon after last month’s upbeat results from Western rivals, such as Pfizer Inc, Moderna, AstraZeneca Plc and from Russia, neither the UAE nor Sinopharm have released detailed data from the pivotal study.

In July, the Gulf Arab state started Phase III clinical trials of the vaccine, developed by Beijing Institute of Biological Product, a unit of Sinopharm’s China National Biotec Group (CNBG).

In September, it authorised emergency use of the vaccine for certain groups, the first such international clearance for a vaccine developed in China.

The analysis also shows “99pc seroconversion rate of neutralizing antibody and 100pc effectiveness in preventing moderate and severe cases of the disease”, the ministry said in a statement carried by the state news agency.

“The analysis shows no serious safety concerns,” it said.

It also said it had officially registered the vaccine, without elaborating, and that 31,000 volunteers across 125 nationalities participated in the UAE trial.

It did not say what, if any, side effects it identified, how many participants have become ill or how many volunteers were given the vaccine or a placebo.

CNBG could not be immediately reached for comment.

The vaccine, which uses an inactivated virus unable to replicate human cells to trigger immune responses, requires two doses, past trial data has showed.

The UAE trial is a partnership between CNBG, Abu Dhabi-based artificial intelligence company Group 42 (G42) and the Abu Dhabi Department of Health.

Sinopharm and G42 have also expanded the trial to Egypt, Jordan and Bahrain.

Abu Dhabi, the UAE’s capital, this week said it was seeking volunteers to take part in clinical trials of Russia’s Covid-19 vaccine, known as Sputnik V.

The UAE, with a population of around nine million, has recorded 178,837 infections and 596 deaths from the disease.

The vaccine is among the three most advanced candidates from China in terms of development and has been used to vaccinate around one million people in the country under its emergency use programme.

Opinion

Editorial

Another U-turn?
Updated 07 Oct, 2022

Another U-turn?

The PTI’s decision to take back its resignations could herald a twist in the tussle playing out in Islamabad.
Renewed TTP threat
07 Oct, 2022

Renewed TTP threat

THE interior ministry’s call for ‘extreme vigilance’ and instructions to security forces to conduct ‘search...
Women’s gala in GB
07 Oct, 2022

Women’s gala in GB

REGRESSIVE forces, once again, nearly had their way — this time in Gilgit-Baltistan. A three-day sporting gala for...
‘Draconian’ law
06 Oct, 2022

‘Draconian’ law

THE debate over what it means to be ‘sadiq’ and ‘ameen’ has reignited after the incumbent Supreme Court ...
Welcome clarity
Updated 06 Oct, 2022

Welcome clarity

There needs to be consensus amongst all political actors that matters of governance should be the exclusive domain of civilians.
Car purchases
06 Oct, 2022

Car purchases

IF we are in the market to buy a new car, we end up paying a significantly large amount as premium over the sticker...